Review: taking Tarceva and Pepcid together


Summary

Drug interactions are reported among people who take Tarceva and Pepcid together. This review analyzes the effectiveness and drug interactions between Tarceva and Pepcid. It is created by eHealthMe based on reports of 312 people who take the same drugs from FDA and social media, and is updated regularly.

You are not alone

Join a support group for people who take Tarceva and Pepcid >>>

Personalized health information

On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA and social media since 1977. Our tools are free and anonymous. 86 million people have used us. 300+ peer-reviewed medical journals have referenced our original studies. Start now >>>


Tarceva

Tarceva has active ingredients of erlotinib hydrochloride. It is often used in malignant respiratory tract neoplasm. (latest outcomes from Tarceva 16,312 users)

Pepcid

Pepcid has active ingredients of famotidine. It is often used in gastrooesophageal reflux disease. (latest outcomes from Pepcid 24,529 users)

On Aug, 30, 2016

312 people who take Tarceva, Pepcid are studied.


Number of reports submitted per year:

Tarceva and Pepcid drug interactions.

Drug effectiveness over time:

Tarceva:
  • < 1 month: 0.0% - (0 of 0 people)
  • 1 - 6 months: 100.0% - (1 of 1 people)
  • 6 - 12 months: 0.0% - (0 of 0 people)
  • 1 - 2 years: 0.0% - (0 of 0 people)
  • 2 - 5 years: 0.0% - (0 of 0 people)
  • 5 - 10 years: 0.0% - (0 of 0 people)
  • 10+ years: 0.0% - (0 of 0 people)
  • not specified: 0.0% - (0 of 0 people)
Pepcid:
  • < 1 month: 0.0% - (0 of 1 people)
  • 1 - 6 months: 0.0% - (0 of 0 people)
  • 6 - 12 months: 0.0% - (0 of 0 people)
  • 1 - 2 years: 0.0% - (0 of 0 people)
  • 2 - 5 years: 0.0% - (0 of 0 people)
  • 5 - 10 years: 0.0% - (0 of 0 people)
  • 10+ years: 0.0% - (0 of 0 people)
  • not specified: 0.0% - (0 of 0 people)

Drug effectiveness by gender:

Tarceva:
  • female: 0.0% - (0 of 0 people)
  • male: 100.0% - (1 of 1 people)
Pepcid:
  • female: 0.0% - (0 of 0 people)
  • male: 0.0% - (0 of 1 people)

Drug effectiveness by age:

Tarceva:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 0 people)
  • 20-29: 0.0% - (0 of 0 people)
  • 30-39: 0.0% - (0 of 0 people)
  • 40-49: 0.0% - (0 of 0 people)
  • 50-59: 100.0% - (1 of 1 people)
  • 60+: 0.0% - (0 of 0 people)
Pepcid:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 0 people)
  • 20-29: 0.0% - (0 of 0 people)
  • 30-39: 0.0% - (0 of 0 people)
  • 40-49: 0.0% - (0 of 0 people)
  • 50-59: 0.0% - (0 of 1 people)
  • 60+: 0.0% - (0 of 0 people)

Most common drug interactions over time *:

< 1 month:
  • malignant neoplasm progression
  • diarrhoea
  • dermatitis acneiform
  • anaemia
  • pyrexia
  • decreased appetite
  • platelet count decreased
  • rash
  • interstitial lung disease
  • neoplasm malignant
1 - 6 months:
  • anaemia
  • dermatitis acneiform
  • malignant neoplasm progression
  • diarrhoea
  • paronychia
  • neoplasm malignant
  • decreased appetite
  • insomnia
  • rash
  • constipation
6 - 12 months:
  • pneumonia
  • deep vein thrombosis
  • asthenia
  • cardiac arrest
  • death
  • decreased appetite
  • hyponatraemia
  • rash
  • small intestinal obstruction
  • supraventricular tachycardia
1 - 2 years:
  • gout
  • hiccups
  • irritable bowel syndrome
  • atelectasis
  • hypotension
  • tachycardia
  • rash
  • bronchitis
  • constipation
  • gastritis
2 - 5 years:
  • cardiopulmonary failure
  • vomiting
  • focal segmental glomerulosclerosis
not specified:
  • pneumonia
  • death
  • rash
  • decreased appetite
  • dyspnoea
  • malignant neoplasm progression
  • diarrhoea
  • deep vein thrombosis
  • pulmonary embolism
  • pleural effusion

Most common drug interactions by gender *:

female:
  • death
  • malignant neoplasm progression
  • anaemia
  • pneumonia
  • rash
  • decreased appetite
  • fatigue
  • diarrhoea
  • pulmonary embolism
  • respiratory failure
male:
  • pneumonia
  • rash
  • decreased appetite
  • diarrhoea
  • malignant neoplasm progression
  • dyspnoea
  • pyrexia
  • pleural effusion
  • back pain
  • neoplasm malignant

Most common drug interactions by age *:

30-39:
  • malignant neoplasm progression
  • rash
  • akathisia
  • aspartate aminotransferase increased
  • blood alkaline phosphatase increased
  • diarrhoea
  • hypocalcaemia
  • adenosquamous cell lung cancer
  • blood bilirubin increased
  • blood creatinine increased
40-49:
  • hypophagia
  • abdominal pain
  • alanine aminotransferase increased
  • aspartate aminotransferase increased
  • gastrointestinal haemorrhage
  • general physical health deterioration
  • hypoalbuminaemia
  • nausea
  • dermatitis acneiform
  • anhedonia
50-59:
  • anaemia
  • neoplasm malignant
  • decreased appetite
  • diarrhoea
  • pulmonary embolism
  • fatigue
  • insomnia
  • dyspnoea
  • anxiety
  • dermatitis acneiform
60+:
  • malignant neoplasm progression
  • pneumonia
  • rash
  • death
  • diarrhoea
  • decreased appetite
  • interstitial lung disease
  • anaemia
  • hepatic function abnormal
  • dermatitis acneiform

* Approximation only. Some reports may have incomplete information.

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

Do you take Tarceva and Pepcid?

Can you answer these questions?

More questions for: Tarceva, Pepcid

You may be interested in these reviews

More reviews for: Tarceva, Pepcid

On eHealthMe, Tarceva (erlotinib hydrochloride) is often used to treat malignant respiratory tract neoplasm. Pepcid (famotidine) is often used to treat gastrooesophageal reflux disease. Find out below the conditions the drugs are used for and how effective they are.

What is the drug used for and how effecitve is it:


NOTE: The study is based on active ingredients and brand name. Other drugs that have the same active ingredients (e.g. generic drugs) are NOT considered.

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.